E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Major Depressive Disorder (MDD) |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025453 |
E.1.2 | Term | Major depressive disorder NOS |
E.1.2 | System Organ Class | 100000004873 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of seltorexant 20 mg compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with MDDIS (major depressive disorder with insomnia symptoms) who have had an inadequate response to current antidepressant therapy with an SSRI (serotonin-norepinephrine reuptake inhibitor) or SNRI (serotonin-norepinephrine reuptake inhibitor) |
|
E.2.2 | Secondary objectives of the trial |
To assess the efficacy of seltorexant compared with placebo in participants with MDDIS as adjunctive therapy to an antidepressant on patient-reported assessment of sleep outcomes.
To assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in participants with MDDIS on the following: - MDD symptoms other than insomnia symptoms. - Patient-reported assessment of sleep outcomes
To assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in participants with MDDIS on the following: - Core symptoms of depression. - Response of depressive symptoms - Patient-reported symptoms of depression |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Pharmacogenomic (DNA/RNA) evaluations: Blood samples for genetic research will be collected from participants who consent separately to this component of the study (where local regulations permit) to allow for the potential identification of genetic, epigenetic and/or transcription factors that may influence the pharmacokinetic (PK), efficacy, safety, or tolerability of seltorexant and to identify genetic and/or epigenetic factors associated with MDDIS. Participation in genetic research is optional. |
|
E.3 | Principal inclusion criteria |
Each potential participant must satisfy all of the following criteria to be enrolled in the study: ● Male or female, aged 18 to 74 years (inclusive). ● Meet DSM-5 diagnostic criteria for MDD, without psychotic features The length of the current depressive episode must be =24 months prior to randomization ● Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The adequate response is defined as an antidepressant treatment for at least 6 weeks on a stable dose (and no antidepressant treatment for at least 6 weeks on a stable dose (and no greater than 18 months in the current episode) or above the minimum therapeutic dose specified in the MGH-ATRQ, must include the participant's current antidepressant treatment ● Have a HDRS-17 total score ≥20 at the first screening interview and must not demonstrate a clinically significant improvement (ie, an improvement of >20% on their HDRS-17 total score) from the first to the second independent HDRS-17 rating, and must have a HDRS-17 total score =18 at the second screening interview ● Have a patient version of the ISI total score ≥15 as well as a clinician version of the ISI total score ≥15 at the second screening visit. ● Body mass index (BMI) between 18 and 40 kg/m2 inclusive (BMI=weight/height2).
Note: other protocol inclusion criteria may also apply. |
|
E.4 | Principal exclusion criteria |
Any potential participant who meets any of the following criteria will be excluded from participating in the study: ● Has a current or recent history of homicidal ideation or serious suicidal ideation within the past 3 months or history of suicidal behavior within the past 6 months ● Has a history of treatment resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode ● Current active DSM-5 diagnosis of obsessive-compulsive disorder, posttraumatic stress disorder, anorexia nervosa, bulimia nervosa, or fibromyalgia. These disorders need to be in remission for at least 1 year for the participant to be enrolled. ● Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, or somatoform disorders. ● Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed. ● Has a history of moderate to severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening or positive test result(s) for alcohol and/or drugs of abuse. ● Has an unstable medical condition such as diabetes, thyroid disease, renal insufficiency, or hepatic disease. Stable illnesses may be allowed.
Note: other protocol exclusion criteria may also apply. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline to Day 43 in the MADRS total score. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Change from baseline to Day 43 in the MADRS without sleep item (MADRS-WOSI) total score. - Change from baseline to Day 43 in sleep disturbance using the Patient Reported Outcome Measurement Information System Sleep Disturbance |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 14 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Chile |
Korea, Republic of |
Malaysia |
Ukraine |
United States |
Denmark |
Finland |
Poland |
Slovakia |
Argentina |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 24 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 10 |